In contrast, our CSF proteomic study, focusing on adult type III SMA patients after a 6-month course of nusinersen treatment, did not reveal statistically significant changes in MCP1, IL-1ra or other major inflammatory mediators. The gene discussed is CCL2; the disease is spinal muscular atrophy, type III.